Sartorius Stedim Biotech S.A. (DIM.PA)
EUR 188.3
(1.02%)
EUR 188.3
(1.02%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.23 Billion EUR | -32.76% |
| 2022 | 1.83 Billion EUR | 18.13% |
| 2021 | 1.55 Billion EUR | 54.88% |
| 2020 | 1 Billion EUR | 33.99% |
| 2019 | 748.34 Million EUR | 18.87% |
| 2018 | 629.56 Million EUR | 13.47% |
| 2017 | 554.82 Million EUR | 5.32% |
| 2016 | 526.82 Million EUR | 16.61% |
| 2015 | 451.78 Million EUR | 32.24% |
| 2014 | 341.65 Million EUR | 16.55% |
| 2013 | 293.12 Million EUR | 6.78% |
| 2012 | 274.5 Million EUR | 15.14% |
| 2011 | 238.42 Million EUR | 10.56% |
| 2010 | 215.65 Million EUR | 13.31% |
| 2009 | 190.33 Million EUR | 8.26% |
| 2008 | 175.8 Million EUR | 47.24% |
| 2007 | 119.4 Million EUR | -51.4% |
| 2006 | 245.67 Million EUR | 8.47% |
| 2005 | 226.48 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 275.4 Million EUR | -10.09% |
| 2024 Q1 | 308.4 Million EUR | 21.8% |
| 2024 Q2 | 306.3 Million EUR | -0.68% |
| 2023 Q2 | 324.9 Million EUR | -13.24% |
| 2023 Q1 | 374.5 Million EUR | -20.84% |
| 2023 Q4 | 253.2 Million EUR | -9.86% |
| 2023 Q3 | 280.9 Million EUR | -13.54% |
| 2023 FY | 1.23 Billion EUR | -32.76% |
| 2022 FY | 1.83 Billion EUR | 18.13% |
| 2022 Q4 | 473.1 Million EUR | 2.62% |
| 2022 Q1 | 454.5 Million EUR | 11.59% |
| 2022 Q2 | 445.9 Million EUR | -1.89% |
| 2022 Q3 | 461 Million EUR | 3.39% |
| 2021 FY | 1.55 Billion EUR | 54.88% |
| 2021 Q1 | 351.8 Million EUR | 30.38% |
| 2021 Q4 | 407.3 Million EUR | -0.63% |
| 2021 Q3 | 409.9 Million EUR | 6.66% |
| 2021 Q2 | 384.3 Million EUR | 9.24% |
| 2020 FY | 1 Billion EUR | 33.99% |
| 2020 Q2 | 234.6 Million EUR | 5.34% |
| 2020 Q1 | 222.7 Million EUR | 16.69% |
| 2020 Q4 | 269.83 Million EUR | -2.24% |
| 2020 Q3 | 276 Million EUR | 17.65% |
| 2019 Q1 | 177.3 Million EUR | 11.96% |
| 2019 FY | 748.34 Million EUR | 18.87% |
| 2019 Q4 | 190.84 Million EUR | -0.39% |
| 2019 Q3 | 191.6 Million EUR | 1.59% |
| 2019 Q2 | 188.6 Million EUR | 6.37% |
| 2018 Q3 | 164.9 Million EUR | 3.65% |
| 2018 Q2 | 159.1 Million EUR | 8.01% |
| 2018 Q1 | 147.3 Million EUR | 1.85% |
| 2018 Q4 | 158.36 Million EUR | -3.96% |
| 2018 FY | 629.56 Million EUR | 13.47% |
| 2017 Q3 | 134.2 Million EUR | -3.52% |
| 2017 Q4 | 144.62 Million EUR | 7.77% |
| 2017 Q1 | 137.3 Million EUR | 6.42% |
| 2017 FY | 554.82 Million EUR | 5.32% |
| 2017 Q2 | 139.1 Million EUR | 1.31% |
| 2016 Q1 | 125.5 Million EUR | 16.76% |
| 2016 FY | 526.82 Million EUR | 16.61% |
| 2016 Q4 | 129.02 Million EUR | -8.5% |
| 2016 Q3 | 141 Million EUR | 7.39% |
| 2016 Q2 | 131.3 Million EUR | 4.62% |
| 2015 FY | 451.78 Million EUR | 32.24% |
| 2015 Q1 | 102.8 Million EUR | 16.02% |
| 2015 Q4 | 107.48 Million EUR | -14.83% |
| 2015 Q3 | 126.2 Million EUR | 9.45% |
| 2015 Q2 | 115.3 Million EUR | 12.16% |
| 2014 Q3 | 85.2 Million EUR | -0.35% |
| 2014 FY | 341.65 Million EUR | 16.55% |
| 2014 Q1 | 77.9 Million EUR | 8.46% |
| 2014 Q2 | 85.5 Million EUR | 9.76% |
| 2014 Q4 | 88.6 Million EUR | 4.0% |
| 2013 Q4 | 71.82 Million EUR | 0.31% |
| 2013 FY | 293.12 Million EUR | 6.78% |
| 2013 Q1 | 68.7 Million EUR | 5.78% |
| 2013 Q2 | 80.9 Million EUR | 17.76% |
| 2013 Q3 | 71.6 Million EUR | -11.5% |
| 2012 Q4 | 64.94 Million EUR | 0.0% |
| 2012 Q2 | 69.4 Million EUR | 0.0% |
| 2012 FY | 274.5 Million EUR | 15.14% |
| 2011 FY | 238.42 Million EUR | 10.56% |
| 2011 Q2 | 60.2 Million EUR | 0.0% |
| 2010 FY | 215.65 Million EUR | 13.31% |
| 2010 Q2 | 54.7 Million EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2009 FY | 190.33 Million EUR | 8.26% |
| 2008 FY | 175.8 Million EUR | 47.24% |
| 2007 FY | 119.4 Million EUR | -51.4% |
| 2006 FY | 245.67 Million EUR | 8.47% |
| 2005 FY | 226.48 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Crossject Société Anonyme | -6.13 Million EUR | 20205.949% |
| Safe Orthopaedics SA | 4.1 Million EUR | -29941.403% |
| Spineway SA | 1.55 Million EUR | -79429.336% |
| Amplitude Surgical SA | 37.2 Million EUR | -3215.504% |
| EssilorLuxottica Société anonyme | 16.07 Billion EUR | 92.324% |
| bonyf N.V. | 26.41 Thousand EUR | -4669772.038% |